Press releases

16 September, 2022

Abliva to participate in World Mitochondrial Disease Week 2022

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will par ...

20 June, 2022

Spots left: Abliva’s Fireside Chat in Lund and Stockholm

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and inves ...

14 June, 2022

Meet Abliva live: Fireside Chat in Lund and Stockholm

20 May, 2022

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2022 held its Annual General Meeting (“AGM”). A summary of the resolutions follows.

19 May, 2022

Regulatory

Abliva to issue the Q1 Interim Report by May 31st

19 April, 2022

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 1 p.m. on Friday, 20 May 2022 at Medicon Village, Scheeletorget ...

14 January, 2022

Regulatory

Resolution at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolution follows. The resolution was passed unanimously.

21 December, 2021

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) held at 11.00 a.m. on Friday 14 January 2022 at Medico ...

24 November, 2021

Regulatory

Abliva

Press releases

Abliva to participate in World Mitochondrial Disease Week 2022

Spots left: Abliva’s Fireside Chat in Lund and Stockholm

Meet Abliva live: Fireside Chat in Lund and Stockholm

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva to issue the Q1 Interim Report by May 31st

Notice of Annual General Meeting of Abliva AB (publ)

Resolution at the Extraordinary General Meeting in Abliva AB (publ)

Notice of Extraordinary General Meeting of Abliva AB (publ)

Abliva’s IND for clinical development of KL1333 approved by FDA

Abliva to participate in World Mitochondrial Disease Week 2021

Abliva drug candidate NV354 to progress to clinical development following positive regulatory review

Meet Abliva’s CEO live: Fireside Chat in Stockholm and Lund